If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Form 8 (DD) - Touchstone Innovations Plc.

24 May 2017 11:17

FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Invesco Limited
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Touchstone Innovations Plc.
(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Acting in concert with both Touchstone Innovations Plc. and with the IP Group Plc.
(e) Date dealing undertaken: 23.05.2017
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES :

IP Group Plc.

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

Class of relevant security: 3 1/33p ordinary

GB00B170L953

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 62,898,455 39.01
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

62,898,455 39.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

Class of relevant security Purchase/sale Number of securities Price per unit

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
Date of disclosure: 24 May 2017
Contact name: Philippa Holmes
Telephone number: 01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005542/en/

Copyright Business Wire 2017

Date   Source Headline
7th Jun 20177:00 amRNSForm 8 (OPD) IP Group PLC
6th Jun 201711:19 amRNSForm 8.3 - Touchstone Innovations
5th Jun 201712:46 pmRNSForm 8.3 - Touchstone Innovations Plc
1st Jun 20172:41 pmBUSForm 8.3 - Touchstone Innovations plc
1st Jun 20177:00 amRNSChairman's letter to shareholders
31st May 20175:58 pmRNSForm 8.5 (EPT/RI) - Touchstone Innovations Plc
31st May 201712:01 pmRNSForm 8.3 - Touchstone Innovations Plc
30th May 20177:00 amRNSForm 8.3 - Touchstone Innovations Plc
26th May 201712:29 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:15 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:14 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:10 pmRNSForm 8.3 - IP Group Plc
24th May 20172:55 pmRNSForm 8.3 - IP Group plc
24th May 20172:52 pmRNSForm 8.3 - Touchstone Innovations plc
24th May 20172:51 pmRNSForm 8.3 - IP Group Plc
24th May 20172:41 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 20171:15 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 201711:17 amBUSForm 8 (DD) - Touchstone Innovations Plc.
23rd May 201712:05 pmRNSUpdate on possible offer
23rd May 201711:45 amRNSForm 8.3 - Touchstone Innovations Plc
23rd May 201710:33 amRNSStatement re Possible Offer
23rd May 20177:01 amRNSStatement re Possible Offer
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
6th Apr 20177:00 amRNSInnovations provides seed funding for Cardian
31st Mar 20177:00 amRNSHalf Yearly Report
20th Mar 20177:05 amRNSInnovations supports funding round in Pulmocide
16th Mar 20177:00 amRNSInnovations invests in Cell Medica funding round
14th Mar 20177:00 amRNSInnovations supports funding round in Resolver
6th Mar 20177:00 amRNSInnovations leads £12m funding round in Garrison
28th Feb 201711:11 amRNSNotice of Results
21st Feb 20177:03 amRNSCell Medica granted FDA Fast Track designation
26th Jan 20172:00 pmRNSDirectorate Change
5th Jan 20177:00 amRNSChange of name to Touchstone Innovations plc
4th Jan 20179:00 amRNSAppointment of Joint Broker
20th Dec 201612:03 pmRNSPsiOxus signs exclusive licence agreement with BMS
28th Nov 20167:02 amRNSPortfolio company TopiVert receives IND approval
23rd Nov 20165:56 pmRNSGrant of share options
21st Nov 201612:53 pmRNSResult of AGM
28th Oct 201612:30 pmRNSProposed change of name to Touchstone Innovations
28th Oct 201612:29 pmRNSPosting of Annual Report and Notice of AGM
24th Oct 20167:12 amRNSVeryan announces completion of subject enrolment
13th Oct 20167:00 amRNSFinal Results
10th Oct 20161:02 pmRNSCrescendo Biologics sign collaboration with Takeda
6th Oct 20167:02 amRNSFirst patients dosed in TopiVert's Phase IIa study
3rd Oct 201612:10 pmRNSSale of Innovations portfolio company Permasense
21st Sep 20167:06 amRNSInnovations invests £5.1m in Artios Pharma Limited
14th Sep 201612:02 pmRNSNotice of Results
13th Sep 20164:08 pmRNSTR-1: Notification of major interest in shares
9th Sep 20161:15 pmRNSHolding(s) in Company
6th Sep 20164:17 pmRNSEdison issues update on Imperial Innovations (IVO)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.